Syntric Medical

Lung cancer is the leading cause of cancer-related deaths worldwide, with 260,000 fatalities in Europe and 1.8 million globally each year. A major factor in this grim statistic is late detection and the difficulty of obtaining accurate biopsies—especially in early-stage disease. While biopsies are essential for confirming diagnosis and guiding personalised treatment, their success rate drops dramatically in early stages, from 96% to just 52%.

Syntric Medical is tackling this challenge by developing a solution that helps interventional radiologists achieve precise needle placement during CT-guided lung biopsies—even as patients breathe. Their technology is designed to increase the accuracy and safety of lung cancer diagnosis in early stages, with the potential to improve outcomes for millions of patients worldwide.